TPST logo

TPST
Tempest Therapeutics Inc

12,783
Mkt Cap
$27.54M
Volume
59,026.00
52W High
$12.23
52W Low
$1.50
PE Ratio
-0.30
TPST Fundamentals
Price
$1.86
Prev Close
$1.81
Open
$1.86
50D MA
$1.90
Beta
2.11
Avg. Volume
290,887.75
EPS (Annual)
-$6.33
P/B
32.46
Rev/Employee
$0.00
$12.34
Loading...
Loading...
News
all
press releases
New Strong Buy Stocks for April 10th
ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026.
News Placeholder
More News
News Placeholder
Tempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 Shares
Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) CEO Matthew Angel acquired 231,482 shares of the business's stock in a transaction on Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the completion of...
News Placeholder
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction
The transaction is expected to close in early 2026, provided it receives all required approvals.
News Placeholder
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today
Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.read more...
News Placeholder
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
News Placeholder
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available